Dec. 17, 2018 – Writing from Britain, Dr. Ben Goldacre echoes Angell’s concerns, charging in “Bad Pharma” that the worst misbehavior in the pharmaceutical industry actually occurs not when prescription drugs are being burnished for market, but far earlier in their development. Lackluster compounds are evaluated in ways guaranteed to make them look good, Goldacre writes, then prettied up even further with distorted claims of efficacy. While “bad behavior in marketing departments is unpleasant,” he concludes, the real scientific outrage and the big public danger lie in uniformly dubious practices of drug development.
EMR MATTERS – October 2024 - The challenge is that many in the behavioral health…
TOO LITTLE, TOO LATE? – Dec. 19, 2024 - Assembly Bill 56 (AB 56) proposes…
AND STOPPED DIGGING – Dec. 4, 2024 - In a new interview with The Times,…
NOT JUST IN PENCILS – Dec. 8, 2024 - Americans born before 1966 experienced “significantly…
AS SUCCESSFUL AS EVER – Dec. 3, 2024 - Family Affair actor Johnny Whitaker looked…
ALANON Plus – Dec. 7, 2024 - A high percentage of treatment failures occur due…